World Investment Advisors Makes New $1.44 Million Investment in abrdn Life Sciences Investors $HQL

World Investment Advisors bought a new stake in abrdn Life Sciences Investors (NYSE:HQL) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 92,866 shares of the company’s stock, valued at approximately $1,440,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Raymond James Financial Inc. grew its stake in abrdn Life Sciences Investors by 31.1% during the 1st quarter. Raymond James Financial Inc. now owns 312,531 shares of the company’s stock valued at $3,966,000 after acquiring an additional 74,061 shares in the last quarter. Wolverine Asset Management LLC boosted its holdings in shares of abrdn Life Sciences Investors by 13.8% during the second quarter. Wolverine Asset Management LLC now owns 142,920 shares of the company’s stock worth $1,831,000 after purchasing an additional 17,382 shares during the period. Allspring Global Investments Holdings LLC grew its position in abrdn Life Sciences Investors by 21.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 235,499 shares of the company’s stock valued at $3,017,000 after purchasing an additional 42,015 shares in the last quarter. Needham Investment Management LLC increased its stake in abrdn Life Sciences Investors by 7.4% in the 1st quarter. Needham Investment Management LLC now owns 378,654 shares of the company’s stock valued at $4,805,000 after buying an additional 25,935 shares during the period. Finally, Penserra Capital Management LLC increased its stake in abrdn Life Sciences Investors by 3.0% in the 2nd quarter. Penserra Capital Management LLC now owns 769,657 shares of the company’s stock valued at $9,859,000 after buying an additional 22,736 shares during the period. Hedge funds and other institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Price Performance

Shares of NYSE:HQL opened at $17.25 on Friday. The firm has a fifty day moving average of $17.02 and a two-hundred day moving average of $14.97. abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $17.80.

abrdn Life Sciences Investors Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 12th. Investors of record on Friday, November 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, November 21st. This is a positive change from abrdn Life Sciences Investors’s previous quarterly dividend of $0.42. This represents a $2.00 dividend on an annualized basis and a yield of 11.6%.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.